KeyBank National Association’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.37M Buy
44,144
+3,976
+10% +$748K 0.03% 260
2026
Q1
$7.92M Buy
40,168
+13,148
+49% +$2.54M 0.03% 258
2025
Q4
$4.97M Buy
27,020
+1,227
+5% +$215K 0.02% 300
2025
Q3
$3.96M Sell
25,793
-1,664
-6% -$252K 0.01% 325
2025
Q2
$3.84M Buy
27,457
+402
+1% +$56.3K 0.01% 330
2025
Q1
$3.98M Buy
27,055
+2,897
+12% +$419K 0.02% 312
2024
Q4
$3.17M Buy
24,158
+554
+2% +$77.6K 0.01% 353
2024
Q3
$3.68M Buy
23,604
+157
+0.7% +$25.3K 0.01% 328
2024
Q2
$3.66M Buy
23,447
+8
+0% +$1.2K 0.02% 316
2024
Q1
$3.18M Sell
23,439
-3,525
-13% -$467K 0.01% 332
2023
Q4
$3.63M Buy
26,964
+744
+3% +$96.7K 0.02% 312
2023
Q3
$3.55M Buy
26,220
+25
+0.1% +$3.42K 0.02% 300
2023
Q2
$3.75M Sell
26,195
-6,839
-21% -$1.01M 0.02% 304
2023
Q1
$4.59M Sell
33,034
-308
-0.9% -$41.4K 0.02% 273
2022
Q4
$4.52M Buy
33,342
+1,337
+4% +$168K 0.02% 274
2022
Q3
$3.51M Buy
32,005
+1,169
+4% +$148K 0.02% 291
2022
Q2
$4.08M Sell
30,836
-671
-2% -$88K 0.02% 281
2022
Q1
$4.18M Sell
31,507
-6,022
-16% -$722K 0.02% 288
2021
Q4
$4.37M Buy
37,529
+138
+0.4% +$16.2K 0.02% 290
2021
Q3
$4.49M Buy
37,391
+2,074
+6% +$241K 0.02% 281
2021
Q2
$4.23M Buy
35,317
+166
+0.5% +$18.2K 0.02% 285
2021
Q1
$3.5M Buy
35,151
+746
+2% +$75K 0.02% 301
2020
Q4
$3.44M Sell
34,405
-139
-0.4% -$14.7K 0.02% 295
2020
Q3
$3.79M Sell
34,544
-30
-0.1% -$3.34K 0.02% 277
2020
Q2
$3.66M Buy
34,574
+10
+0% +$1.03K 0.02% 279
2020
Q1
$3.09M Buy
34,564
+35
+0.1% +$3.29K 0.02% 285
2019
Q4
$3.44M Buy
34,529
+1,275
+4% +$120K 0.02% 302
2019
Q3
$2.96M Buy
33,254
+97
+0.3% +$8.41K 0.02% 307
2019
Q2
$2.74M Buy
33,157
+1,124
+4% +$88.1K 0.02% 323
2019
Q1
$2.59M Buy
32,033
+2,791
+10% +$220K 0.02% 320
2018
Q4
$2.22M Buy
29,242
+3,050
+12% +$238K 0.01% 325
2018
Q3
$2.07M Sell
26,192
-14,192
-35% -$1.07M 0.01% 352
2018
Q2
$2.84M Sell
40,384
-91
-0.2% -$6.55K 0.02% 304
2018
Q1
$2.83M Sell
40,475
-565
-1% -$39.1K 0.02% 301
2017
Q4
$2.85M Buy
41,040
+258
+0.6% +$17.4K 0.02% 299
2017
Q3
$2.76M Sell
40,782
-1,175
-3% -$74.2K 0.02% 305
2017
Q2
$2.86M Sell
41,957
-1,060
-2% -$69.2K 0.02% 297
2017
Q1
$2.68M Buy
43,017
+1,836
+4% +$107K 0.02% 314
2016
Q4
$2.25M Sell
41,181
-2,358
-5% -$134K 0.01% 346
2016
Q3
$2.86M Buy
43,539
+3,528
+9% +$231K 0.02% 305
2016
Q2
$2.42M Sell
40,011
-625
-2% -$36.3K 0.02% 316
2016
Q1
$2.29M Sell
40,636
-2,464
-6% -$148K 0.02% 321
2015
Q4
$2.93M Buy
43,100
+894
+2% +$58.6K 0.02% 292
2015
Q3
$2.69M Sell
42,206
-524
-1% -$34.5K 0.02% 311
2015
Q2
$2.72M Sell
42,730
-993
-2% -$68K 0.02% 324
2015
Q1
$2.99M Sell
43,723
-657
-1% -$45.6K 0.02% 324
2014
Q4
$3.12M Buy
44,380
+2,867
+7% +$205K 0.02% 312
2014
Q3
$2.97M Sell
41,513
-952
-2% -$69.7K 0.02% 324
2014
Q2
$3.16M Sell
42,465
-16,060
-27% -$1.16M 0.02% 321
2014
Q1
$3.8M Buy
58,525
+715
+1% +$46.2K 0.03% 290
2013
Q4
$3.43M Buy
57,810
+2,043
+4% +$111K 0.02% 303
2013
Q3
$2.9M Buy
55,767
+1,187
+2% +$59.6K 0.02% 321
2013
Q2
$2.58M Buy
+54,580
New +$2.78M 0.01% 588

Other funds holding AZN

KeyBank National Association's AZN Position: Q2 2026 in Review

KeyBank National Association increased its AstraZeneca (AZN) stake by 9.9% in Q2 2026, buying an estimated $748K and bringing the position to 44,144 shares worth $8.37M. The position accounts for 0.03% of the portfolio, ranked #260.

KeyBank National Association first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • KeyBank National Association held 44,144 shares of AstraZeneca worth $8.37M as of Q2 2026.
  • KeyBank National Association bought 3,976 AstraZeneca shares in Q2 2026, an estimated $748K.
  • AstraZeneca made up 0.03% of KeyBank National Association's portfolio in Q2 2026, its #260 holding.
  • KeyBank National Association first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.